FDA-cleared profile

MediAI-OA

Crescom Co., Ltd. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.

Clinical role
Detection and assessment aid for knee OA features; human interpretation remains required.
Images and patients
X-ray/Radiography · Knee joint
Key limitation
Keep in mind: Not in lieu of full patient evaluation and not to be solely relied on to make or confirm a diagnosis; trained professional interpretation is required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Knee joint Input: DICOM CR or DX knee radiographs; the comparison table also lists jpeg/jpg/png; standing, fixed-flexion knee radiographs.
  • Who uses it?Intended users: Trained professionals including radiologists, orthopedists, physicians, and medical technicians.
  • What does the software produce?Output: KL grade 0/1, 2, 3, or 4; presence/absence of JSN, osteophytes, and sclerosis; screen, web-report, markup-image, and static textual-report outputs.
  • What is its most important limitation?Key limitation: Not in lieu of full patient evaluation and not to be solely relied on to make or confirm a diagnosis; trained professional interpretation is required.

Clinical takeaway. Clinical role: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.

Evidence takeaway. Evidence from the reviewed source record: FDA K253172 packet describes an independent site-separated performance test with 1,173 independent test subjects and 11,383 knees. Key test endpoints were KL >=2 sensitivity 87.6% (95% CI 86.6%-88.5%) and specificity 86.5% (85.6%-87.3%); JSN >= OARSI grade 1 sensitivity 88.0% and specificity 86.4%; osteophyte >= OARSI grade 1 sensitivity 89.7% and specificity 82.3%; sclerosis sensitivity 88% and specificity 90%.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Detection and assessment aid for knee OA features; human interpretation remains required.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM CR or DX knee radiographs; the comparison table also lists jpeg/jpg/png; standing, fixed-flexion knee radiographs.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
KL grade 0/1, 2, 3, or 4; presence/absence of JSN, osteophytes, and sclerosis; screen, web-report, markup-image, and static textual-report outputs.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Healthcare facilities and hospitals.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained professionals including radiologists, orthopedists, physicians, and medical technicians.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not in lieu of full patient evaluation and not to be solely relied on to make or confirm a diagnosis; trained professional interpretation is required.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K253172 packet describes an independent site-separated performance test with 1,173 independent test subjects and 11,383 knees. Key test endpoints were KL >=2 sensitivity 87.6% (95% CI 86.6%-88.5%) and specificity 86.5% (85.6%-87.3%); JSN >= OARSI grade 1 sensitivity 88.0% and specificity 86.4%; osteophyte >= OARSI grade 1 sensitivity 89.7% and specificity 82.3%; sclerosis sensitivity 88% and specificity 90%.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K253172 packet describes an independent site-separated performance test with 1,173 independent test subjects and 11,383 knees. Key test endpoints were KL >=2 sensitivity 87.6% (95% CI 86.6%-88.5%) and specificity 86.5% (85.6%-87.3%); JSN >= OARSI grade 1 sensitivity 88.0% and specificity 86.4%; osteophyte >= OARSI grade 1 sensitivity 89.7% and specificity 82.3%; sclerosis sensitivity 88% and specificity 90%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Endpoint-specific sensitivity: KL >=2 87.6%; KL 0/1 86.5%; KL 2 71.7%; KL 3 75.0%; KL 4 90.5%; JSN >=1 88.0%; osteophyte >=1 89.7%; sclerosis 88.0%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

These knee-radiograph classification endpoints must not be collapsed into one device-level diagnostic sensitivity.

Reported specificity
Endpoint-specific specificity: KL >=2 86.5%; KL 0/1 87.6%; KL 2 86.2%; KL 3 97.2%; KL 4 99.5%; JSN >=1 86.4%; osteophyte >=1 82.3%; sclerosis 90.0%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

The previous baseline duplicated sensitivity values here; these are the FDA-reported endpoint-specific specificity values.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

MediAI-OA regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K253172
  • Samplen=1173
  • IndependenceIndependence not established

K253172

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K253172. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CR or DX knee radiographs; the comparison table also lists jpeg/jpg/png; standing, fixed-flexion knee radiographs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K253172: MediAI-OA

  2. Routing

    Source context, not route validation: DICOM-compliant image input and server-side processing are stated; the packet does not establish a specific PACS/RIS routing interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K253172: MediAI-OA

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: KL grade 0/1, 2, 3, or 4; presence/absence of JSN, osteophytes, and sclerosis; screen, web-report, markup-image, and static textual-report outputs.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K253172: MediAI-OA

  5. Viewer/worklist/report

    Unresolved route: KL grade 0/1, 2, 3, or 4; presence/absence of JSN, osteophytes, and sclerosis; screen, web-report, markup-image, and static textual-report outputs.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K253172: MediAI-OA

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
DICOM-compliant image input and server-side processing are stated; the packet does not establish a specific PACS/RIS routing interface.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for MediAI-OA; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253172
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Knee joint
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-06-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K253172 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K253172: MediAI-OA

    U.S. Food and Drug Administration - Published 2026-06-15 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MediAI-OA model card (K253172)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K253172

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K253172 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253930

Overjet Iris Intelligent Imaging System

Overjet, Inc.

Authorized purpose: Overjet Iris is a web-based dental PACS for storing, viewing, and supporting image-quality review of two-dimensional intraoral radiographs, panoramic images, and color photographs.

Modality
X-ray/Radiography
Anatomy
Teeth and maxillofacial anatomy
Decision
2026-04-10
FDA-cleared K250525

Second Opinion® Panoramic

Pearl, Inc.

Authorized purpose: Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth; caries, periapical radiolucency, and impacted third molars
Decision
2025-11-14
FDA-cleared K251002

Videa Dental AI

VideaHealth Inc.

Authorized purpose: Analyzes bitewing, periapical, and panoramic intraoral radiographs from patients aged 3 years and older to identify and localize specified suspected dental findings, historical treatments, and normal anatomy; diagnostic use remains with trained dental professionals.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-09-19
FDA-cleared K250738

YSIO X.pree

Siemens Medical Solutions

Authorized purpose: YSIO X.pree is a digital X-ray system for whole-body radiographic imaging, including skull, chest, abdomen, and extremities, to support diagnostic and therapeutic decisions.

Modality
X-ray/Radiography
Anatomy
Whole body, including skull; chest; abdomen; and extremities
Decision
2025-07-31

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history